Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Judson

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
Cancer Research|October 20, 2004
A gene expression signature associated with metastatic outcome in human leiomyosarcomasYin-Fai Lee, Megan John, Alison Falconer, et al.
Cancer|June 3, 2015
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)Corneel Coens, Winette T A van der Graaf, Jean-Yves Blay, et al.
Acta Oncologica (Stockholm, Sweden)|April 23, 2017
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 studyRobin J Young, Saskia Litière, Michela Lia, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Science Translational Medicine|July 16, 2010
Quinone oxidoreductase-2-mediated prodrug cancer therapyMark R Middleton, Richard Knox, Emma Cattell, et al.
Cancer|February 3, 2011
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcomaAntoine Italiano, Armelle Laurand, Audrey Laroche, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2006
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursMaria Debiec-Rychter, Raf Sciot, Axel Le Cesne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsSimon Pacey, Richard H Wilson, Mike Walton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumorsKim Appleton, Helen J Mackay, Ian Judson, et al.
Journal of Proteomics|April 25, 2021
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometryMartina Milighetti, Lukas Krasny, Alex T J Lee, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
Cancer Research|October 20, 2004
A gene expression signature associated with metastatic outcome in human leiomyosarcomasYin-Fai Lee, Megan John, Alison Falconer, et al.
Cancer|June 3, 2015
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)Corneel Coens, Winette T A van der Graaf, Jean-Yves Blay, et al.
Acta Oncologica (Stockholm, Sweden)|April 23, 2017
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 studyRobin J Young, Saskia Litière, Michela Lia, et al.
Cancer|May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trialAndrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Science Translational Medicine|July 16, 2010
Quinone oxidoreductase-2-mediated prodrug cancer therapyMark R Middleton, Richard Knox, Emma Cattell, et al.
Cancer|February 3, 2011
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcomaAntoine Italiano, Armelle Laurand, Audrey Laroche, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2006
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursMaria Debiec-Rychter, Raf Sciot, Axel Le Cesne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsSimon Pacey, Richard H Wilson, Mike Walton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumorsKim Appleton, Helen J Mackay, Ian Judson, et al.
Journal of Proteomics|April 25, 2021
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometryMartina Milighetti, Lukas Krasny, Alex T J Lee, et al.
Pageof 16